Hemoglobin News and Research

RSS

Prior administration of erythropoietin reduces need for blood transfusions

Anemia increases operative mortality and morbidity in non-cardiac and cardiac surgical procedures. Anemic surgical patients may require more blood transfusions, raising the risk of transfusion-related complications and increasing costs.

7 May 2013

Organic pollutants increase nephropathy risk in diabetes

Individuals with diabetes may reduce their risk for developing nephropathy if they minimize their exposure to persistent organic pollutants, suggest researchers.

29 Apr 2013

Nephropathy risk lowered by glucose, BP control in Type 1 diabetes

Individuals with Type 1 diabetes should keep good control of their blood sugar levels and blood pressure to reduce their risk for developing nephropathy, say researchers.

29 Apr 2013

Serum C-peptide levels predict cardiovascular death risk

Levels of C-peptide predict the risk for death from cardiovascular disease in nondiabetic adults, show data from the US National Health and Nutrition Examination Survey.

25 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

Pioneering research led by Johns Hopkins scientists on the use of partially matched bone marrow transplants to wipe out sickle cell disease has been selected as one of the Top 10 Clinical Research Achievements of 2012 by the Clinical Research Forum.

22 Apr 2013

New combination therapies with anti-sickling capabilities needed for sickle cell disease

Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.

18 Apr 2013

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.

18 Apr 2013

Study finds link between C-peptide levels, heart disease and death in nondiabetic people

High blood levels of the serum C-peptide are linked to heart disease and death in people without diabetes, according to a large study published in CMAJ.

16 Apr 2013

New nanosponge safely removes dangerous toxins from bloodstream

Engineers at the University of California, San Diego have invented a "nanosponge" capable of safely removing a broad class of dangerous toxins from the bloodstream - including toxins produced by MRSA, E. coli, poisonous snakes and bees.

15 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

Study: Glycated hemoglobin levels of children with type 1 diabetes are correlated negatively with household income

Researchers at the University of Montreal have found that the glycated hemoglobin levels of children with type 1 diabetes followed at its affiliated Sainte-Justine Mother and Child University Hospital (CHU Sainte-Justine) is correlated linearly and negatively with household income.

4 Apr 2013

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

The U.S. Food and Drug Administration today approved Invokana (canaglifozin) tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.

30 Mar 2013

Score can predict risk for hospital readmission

A risk score for hospitalized patients can pinpoint those most at risk of having to be readmitted to the hospital for avoidable reasons.

27 Mar 2013

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Neurocrine Biosciences, Inc. today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated.

27 Mar 2013

New model helps identify patients who are at high risk for hospital readmission

Hospital readmissions are a costly problem for patients and for the United States health care system with studies showing nearly 20 percent of Medicare patients are readmitted to the hospital within 30 days of discharge at an annual cost of $17 billion.

26 Mar 2013

Two studies shed light on molecular biology of three blood disorders

Two studies led by investigators at Weill Cornell Medical College shed light on the molecular biology of three blood disorders, leading to novel strategies to treat these diseases.

26 Mar 2013

WUSTL's Wang receives NSF grant to study oxygen consumption rates of individual cells

When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.

21 Mar 2013

Study investigates prognostic indicators for BCa patients treated with RC

A new study from Japan investigated various prognostic indicators, including clinico-pathological and pre-operative hematological factors to develop a novel prognostic factors-based risk stratification model for disease-specific survival in bladder cancer patients treated with radical cystectomy.

19 Mar 2013

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013